T. Manshouri

发表

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

H. Kantarjian, A. Vega-Ruiz, J. Cortes, 2009, Leukemia research.

p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

A. El‐Naggar, V. Pant, Peirong Yang, 2012, Cancer cell.

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

H. Kantarjian, T. Manshouri, A. Quintás-Cardama, 2010, Blood.

Cancer Therapy : Preclinical Heat Shock Protein 90 Inhibitor Is Synergistic with JAK 2 Inhibitor and Overcomes Resistance to JAK 2-TKI in Human Myeloproliferative Neoplasm Cells

K. Bhalla, T. Manshouri, S. Verstovsek, 2011 .

Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells

K. Bhalla, T. Manshouri, S. Verstovsek, 2011, Clinical Cancer Research.

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells

P. Qiu, K. Rajapakshe, C. Coarfa, 2016, Leukemia.

Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies

D. Gilliland, T. Manshouri, A. Quintás-Cardama, 2008, Leukemia.

Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis.

T. Manshouri, C. Bueso-Ramos, M. Keating, 1995, Leukemia & lymphoma.

Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.

M. Gönen, O. Abdel-Wahab, A. Heguy, 2012, Blood.

Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia.

H. Kantarjian, T. Manshouri, E. Freireich, 2000, Leukemia research.

Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations

George A Calin, Hui Yang, Milan Radovich, 2018, Genome research.

Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor

Z. Estrov, D. Harris, H. Kantarjian, 2011, Investigational New Drugs.

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells

K. Bhalla, T. Manshouri, S. Verstovsek, 2022, Blood cancer journal.

Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics

Z. Estrov, T. Manshouri, S. Verstovsek, 2016, Leukemia & lymphoma.

miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.

G. Calin, Z. Estrov, M. Estecio, 2020, JCI insight.

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis

Z. Estrov, H. Kantarjian, T. Manshouri, 2017, Haematologica.

Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms

S. Armstrong, P. Stephens, R. Yelensky, 2014, Proceedings of the National Academy of Sciences.

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.

O. Abdel-Wahab, Z. Estrov, D. Harris, 2013, Blood.

Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.

C. Creighton, Z. Estrov, D. Harris, 2011, Cancer research.

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

M. Konopleva, Z. Estrov, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001

H. Kantarjian, J. Cortes, M. Sever, 2009, International journal of hematology.

The JAK kinase inhibitor CP‐690,550 supresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation

Z. Estrov, H. Kantarjian, J. Cortes, 2008, Cancer science.

Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells

H. Kantarjian, T. Manshouri, A. Quintás-Cardama, 2006, Cancer science.

The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.

H. Kantarjian, T. Manshouri, S. Verstovsek, 2008, Blood.

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia

J. Mestan, H. Kantarjian, J. Cortes, 2005, Clinical Cancer Research.

The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.

Z. Estrov, R. Kurzrock, T. Manshouri, 2002, Blood.

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia

Z. Estrov, R. Kurzrock, T. Manshouri, 2002 .

The regions of α-neurotoxin binding on the extracellular part of the α-subunit of human acetylcholine receptor

M. Atassi, T. Manshouri, B. Mulac‐Jeričević, 1988, Journal of protein chemistry.

Antibody and T-cell recognition of α-bungarotoxin and its synthetic loop-peptides

M. Atassi, T. Manshouri, B. Z. Dolimbek, 1995 .

Downregulation of the p53 tumor suppressor gene and upregulation of the bcl-2 gene in retinoic acid receptor alpha-deficient transgenic mice.

T. Manshouri, E. Freireich, M. Albitar, 2000, International journal of oncology.

Mechanistic basis and efficacy of targeting β-catenin-TCF7L2-JMJD6-MYC axis to overcome resistance to BET inhibitors.

Michael R. Green, Charles Y. Lin, C. Coarfa, 2019, Blood.

Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML

P. Qiu, K. Rajapakshe, C. Coarfa, 2018, Leukemia.

Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome.

E. Estey, D. Neuberg, Z. Estrov, 2002, Leukemia research.

Expression profile of MDM‐2 proteins in chronic lymphocytic leukemia and their clinical relevance

T. Manshouri, C. Bueso-Ramos, M. Keating, 1997, American journal of hematology.

De novo CD5+ Burkitt lymphoma/leukemia.

H. Kantarjian, T. Manshouri, M. Albitar, 1999, American journal of clinical pathology.

Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia.

E. Estey, Z. Estrov, H. Kantarjian, 1999, Leukemia research.

Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia

H. Kantarjian, J. Cortes, T. Manshouri, 2009, Clinical Cancer Research.

Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells

Michael R. Green, C. Coarfa, K. Bhalla, 2021, Blood Cancer Journal.

Targeting cistrome and dysregulated transcriptome of post-MPN sAML

K. Bhalla, T. Manshouri, S. Verstovsek, 2017, Oncotarget.

Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes

Z. Estrov, D. Harris, T. Manshouri, 2019, PloS one.

The dual ABL/SRC inhibitors dasatinib, SKI-606, and INNO-406 are potent inhibitors of T cell acute lymphoblastic leukemia cell lines expressing the NUP214-ABL1 fusion kinase

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.

H. Kantarjian, T. Manshouri, S. Verstovsek, 2017, Blood.

MYELOID NEOPLASIA Correlation of mutation pro ﬁ le and response in patients with myelo ﬁ brosis treated with ruxolitinib

H. Kantarjian, J. Cortes, T. Manshouri, 2015 .

Dynamics of Mutant Alleles in Patients with Advanced Essential Thrombocythemia (ET) or Polycythemia (PV) During Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; Pegasys) Therapy

O. Abdel-Wahab, R. Levine, H. Kantarjian, 2011 .

Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes

E. Estey, H. Kantarjian, T. Manshouri, 2002, Cancer.

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.

H. Kantarjian, J. Cortes, T. Manshouri, 2005, Leukemia research.

Circulating CD20 and CD52 in patients with non‐Hodgkin's lymphoma or Hodgkin's disease

J. Armitage, P. Bierman, J. Vose, 2003, British journal of haematology.

Involvement of retinoic acid receptor-alpha-mediated signaling pathway in induction of CD38 cell-surface antigen.

M. Andreeff, T. Manshouri, T. McQueen, 1997, Blood.

Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia

E. Estey, H. Kantarjian, J. Cortes, 2003, Cancer.

Loss of heterozygosity on chromosome 5 in adults with acute lymphoblastic leukemia.

T. Manshouri, M. Albitar, S. Faderl, 2001, Leukemia research.

Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis

H. Kantarjian, T. Manshouri, S. Verstovsek, 2008, Leukemia.

Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome.

E. Estey, Z. Estrov, H. Kantarjian, 2003, Blood.

Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing

E. Estey, Z. Estrov, H. Kantarjian, 2001, Leukemia.

The prognostic significance of 13q14 deletions in chronic lymphocytic leukemia.

P. Starostik, T. Manshouri, E. Freireich, 1999, Leukemia research.

Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia.

E. Estey, H. Kantarjian, T. Manshouri, 2004, Blood.

Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma

T. Manshouri, M. Keating, F. Giles, 2003, European journal of haematology.

myeloproliferative neoplasms - BCR-ABL The natural history and treatment outcome of blast phase

H. Kantarjian, T. Manshouri, C. Bueso-Ramos, 2011 .

Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B‐cell chronic lymphocytic leukemia

H. Kantarjian, T. Manshouri, M. Keating, 2003, Cancer.

Pentraxin‐3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis

Z. Estrov, T. Manshouri, S. Verstovsek, 2018, British journal of haematology.

Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.

D. Podoloff, T. Manshouri, P. Mclaughlin, 2009 .

Z. Estrov, H. Kantarjian, J. Cortes, 2017, Blood advances.

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)

H. Kantarjian, G. Garcia-Manero, T. Manshouri, 2010, British journal of haematology.

p16INK4A and p15INK4B gene deletions in primary leukemias.

T. Manshouri, M. Keating, M. Albitar, 1995, Blood.

Molecular differences between small and large cells in patients with chronic lymphocytic leukemia

H. Kantarjian, T. Manshouri, M. Keating, 2003, European journal of haematology.

ATM mutations and protein expression are not associated with familial B-CLL cases.

G. Marti, T. Manshouri, M. Dean, 2003, Leukemia research.

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Leukemia research.

The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-α-expressing cells through caspase-3-mediated cleavage of Mcl-1

H. Kantarjian, J. Cortes, T. Manshouri, 2007, Leukemia.

Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.

H. Kantarjian, J. Cortes, T. Manshouri, 2006, Leukemia research.

Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia

K. Do, H. Kantarjian, T. Manshouri, 2003, British journal of haematology.

Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow

T. Manshouri, R. Luthra, S. Verstovsek, 2009, Modern Pathology.

Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy

B. Bernstein, B. Ebert, Mazhar Adli, 2011, Nature.

Biological activities of rat antisera raised against synthetic peptides of human thyrotropin receptor.

M. Atassi, T. Manshouri, S. Sakata, 1993, Endocrine journal.

Autoimmune T-cell recognition sites of human thyrotropin receptor in Graves' disease

M. Atassi, T. Manshouri, K. Okuda, 1993, Molecular and Cellular Endocrinology.

ATM gene deletion in patients with adult acute lymphoblastic leukemia

T. Manshouri, E. Freireich, S. O'brien, 2000, Cancer.

Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.

H. Kantarjian, J. Cortes, T. Manshouri, 2015, Leukemia research.

Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia.

H. Kantarjian, J. Cortes, T. Manshouri, 2002, Blood.

The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.

E. Estey, Z. Estrov, H. Kantarjian, 2000 .

Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance.

K. Do, H. Kantarjian, T. Manshouri, 2003, Blood.

PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study

Z. Estrov, T. Manshouri, S. Verstovsek, 2018, Blood.

Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia.

H. Kantarjian, P. Starostik, T. Manshouri, 1998, Cancer research.

Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

P. Qiu, K. Rajapakshe, C. Coarfa, 2016, Leukemia.

AMN107, Novel Aminopyrimidine Inhibitor of Bcr-Abl, Is Significantly More Potent Than Imatinib Mesylate Against Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells.

Z. Estrov, H. Kantarjian, J. Cortes, 2004 .

Deletions in the 13q14 locus in adult lymphoblastic leukemia

P. Starostik, T. Manshouri, E. Freireich, 2000, Cancer.

Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.

O. Abdel-Wahab, A. Heguy, R. Levine, 2010, Cancer research.

The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia.

Z. Estrov, H. Kantarjian, J. Cortes, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

The Prognostic Significance of p16 INK4a /p14 ARF and p15 INK4b Deletions in Adult Acute Lymphoblastic Leukemia

Z. Estrov, H. Kantarjian, J. Cortes, 1999 .

Differences in CD33 intensity between various myeloid neoplasms.

H. Kantarjian, J. Cortes, T. Manshouri, 2002, American journal of clinical pathology.

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.

H. Kantarjian, J. Cortes, T. Manshouri, 2015, Blood.

Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008, Clinical Cancer Research.

Abnormal expression of MDM-2 in breast carcinomas

N. Sneige, T. Manshouri, C. Bueso-Ramos, 2005, Breast Cancer Research and Treatment.

hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies.

M. McArthur, A. Multani, T. Manshouri, 2015, Cancer cell.

The prognostic significance of bone marrow levels of neurofibromatosis‐1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome

H. Kantarjian, T. Manshouri, M. Keating, 2003, Cancer.

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010, Blood.

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008, Leukemia.

Clinical significance of fragile histidine triad gene expression in adult acute lymphoblastic leukemia.

H. Kantarjian, T. Manshouri, S. Kornblau, 2001, Leukemia research.

Significance of FHIT expression in chronic myelogenous leukemia.

C. Croce, H. Kantarjian, J. Cortes, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Molecular abnormalities of mdm-2 in human sarcomas.

T. Manshouri, M. Albitar, A. Glassman, 1995, International journal of oncology.

The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia.

Z. Estrov, T. Manshouri, M. Albitar, 1999, Cytokines, cellular & molecular therapy.

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes

Z. Estrov, T. Manshouri, S. Verstovsek, 2022, Cell Death & Disease.

Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome

E. Estey, Z. Estrov, T. Manshouri, 2000, Leukemia.

Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells

K. Bhalla, T. Manshouri, S. Verstovsek, 2013, Molecular Cancer Therapeutics.

Imatinib effect on growth and signal transduction in polycythemia vera.

W. Vainchenker, J. Cortes, T. Manshouri, 2007, Experimental hematology.

syndromes Angiogenesis in acute and chronic leukemias and myelodysplastic

E. Estey, Z. Estrov, H. Kantarjian, 2013 .

Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia.

H. Kantarjian, J. Cortes, T. Manshouri, 2003, Leukemia research.

Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.

E. Estey, Z. Estrov, T. Manshouri, 2000, Blood.

Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia.

B. Barlogie, H. Kantarjian, T. Manshouri, 2000, Blood.

High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia.

Z. Estrov, H. Kantarjian, T. Manshouri, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation

Z. Estrov, D. Harris, H. Kantarjian, 2008, Clinical Cancer Research.

lymphocytic leukemia and is of prognostic significance Circulating CD20 is detectable in the plasma of patients with chronic

K. Do, H. Kantarjian, T. Manshouri, 2013 .

Circulating CD 20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance

K. Do, H. Kantarjian, T. Manshouri, 2003 .

Myelodysplastic syndrome is not merely "preleukemia".

Yu Shen, Diane D. Liu, E. Estey, 2002, Blood.

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.

H. Kantarjian, J. Cortes, T. Manshouri, 2007, Blood.

Bone marrow cyclooxygenase‐2 levels are elevated in chronic‐phase chronic myeloid leukaemia and are associated with reduced survival

H. Kantarjian, T. Manshouri, M. Talpaz, 2002, British journal of haematology.

Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome

H. Kantarjian, J. Cortes, T. Manshouri, 2002, British journal of haematology.

Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL).

H. Kantarjian, T. Manshouri, M. Keating, 2001, Leukemia research.

Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia

H. Kantarjian, J. Cortes, T. Manshouri, 2003, Cancer.

Myelofibrosis osteoclasts are clonal and functionally impaired.

Z. Estrov, A. Multani, T. Manshouri, 2019, Blood.

Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis

C. Creighton, Z. Estrov, D. Harris, 2016, The Journal of experimental medicine.

Highly reproducible detection and semi-quantification of telomerase activity.

E. Estey, T. Manshouri, S. Verstovsek, 2001, BioTechniques.

STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells

Z. Estrov, D. Harris, T. Manshouri, 2021, Oncotarget.

Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL)

K. Do, H. Kantarjian, G. Garcia-Manero, 2002, Leukemia.

Biolog Peptid ical Activities of Rat Antisera Raised es of Human Thyrotropin Receptor against Synthetic

M. Atassi, T. Manshouri, S. Sakata, 2006 .

Biological activities of rabbit antibodies against synthetic human thyrotropin receptor peptides representing thyrotropin binding regions.

M. Atassi, T. Manshouri, S. Sakata, 1992, Biochemical and biophysical research communications.

Localization and synthesis of the hormone-binding regions of the human thyrotropin receptor.

M. Atassi, T. Manshouri, S. Sakata, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO‐406

H. Kantarjian, J. Cortes, T. Manshouri, 2007, Cancer science.

Multidrug resistance protein expression in chronic myeloid leukemia

H. Kantarjian, J. Cortes, T. Manshouri, 1999, Cancer.

Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels.

Diane D. Liu, E. Estey, Yu Shen, 2002, Leukemia research.

JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis.

T. Manshouri, S. Verstovsek, Ying Zhang, 2017, Leukemia research.

Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-κB-dependent manner.

D. Chen, T. Manshouri, S. Verstovsek, 2014, Cell stem cell.

Downregulation of RARα in Mice by Antisense Transgene Leads to a Compensatory Increase in RARβ and RARγ and Development of Lymphoma

T. Manshouri, S. Stass, Huai-En Lin, 1997 .

Design of peptide enzymes (pepzymes): surface-simulation synthetic peptides that mimic the chymotrypsin and trypsin active sites exhibit the activity and specificity of the respective enzyme.

M. Atassi, T. Manshouri, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis of tolerogenic monomethoxypolyethylene glycol and polyvinyl alcohol conjugates of peptides

M. Atassi, T. Manshouri, 1991, Journal of protein chemistry.

Downregulation of RAR alpha in mice by antisense transgene leads to a compensatory increase in RAR beta and RAR gamma and development of lymphoma.

H. Lin, T. Manshouri, S. Stass, 1997, Blood.

Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.

J. Armitage, P. Bierman, J. Vose, 2004, Leukemia research.

Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome

H. Kantarjian, T. Manshouri, S. Verstovsek, 2001, British journal of haematology.

The prognostic significance of p16INK4a/p14ARF locus deletion and MDM‐2 protein expression in adult acute myelogenous leukemia

Z. Estrov, H. Kantarjian, J. Cortes, 2000, Cancer.

Prognostic significance of Tie‐1 protein expression in patients with early chronic phase chronic myeloid leukemia

H. Kantarjian, J. Cortes, T. Manshouri, 2002, Cancer.

High Expression of the Receptor Tyrosine Kinase Tie-1 in Acute Myeloid Leukemia and Myelodysplastic Syndrome

H. Kantarjian, T. Manshouri, S. Verstovsek, 2001, Leukemia & lymphoma.

Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis

Z. Estrov, T. Manshouri, S. Verstovsek, 2020, Haematologica.

Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3.

T. Manshouri, S. Verstovsek, K. Newberry, 2014, Anticancer research.

STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells

Z. Estrov, D. Harris, T. Manshouri, 2022, The Journal of Immunology.

bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use

E. Estey, Z. Estrov, T. Manshouri, 2000 .

High Rates of Molecular Response After Long-Term Follow-up of Patients with Advanced Essential Thrombocythemia (ET) or Polycythemia Vera (PV) Treated with Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS)

O. Kilpivaara, R. Levine, H. Kantarjian, 2010 .

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial

T. Manshouri, S. Verstovsek, K. Trunzer, 2023, Haematologica.

Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

Z. Estrov, T. Manshouri, E. Freireich, 2000 .

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

K. Bhalla, T. Manshouri, S. Verstovsek, 2019, Blood.